$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Hyaluronic Acid in Drug Delivery Systems 원문보기

Journal of pharmaceutical investigation, v.40 special issue, 2010년, pp.33 - 43  

Jin, Yu-Jin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ,  Ubonvan, Termsarasab (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ,  Kim, Dae-Duk (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)

Abstract AI-Helper 아이콘AI-Helper

Hyaluronic acid (HA) is a biodegradable, biocompatible, non-toxic, non-immunogenic and non-inflammatory linear polysaccharide, which has been used for various medical applications including arthritis treatment, wound healing, ocular surgery, and tissue augmentation. Because of its mucoadhesive prope...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

성능/효과

  • , 2005). The advantages of this ternary complex were facile formulation process, mild preparative conditions, high entrapment efficiency, biodegradable components, biocompatibility, pH-sensitivity, and extended release capability. On the other hand, porous microparticles (PMs) with a low density (<0.
본문요약 정보가 도움이 되었나요?

참고문헌 (107)

  1. Akima, K., Ito, H., Iwata, Y., Matsuo, K., Watari, N., Yanagi, M., Hagi, H., Oshima, K., Yagita, A., Atomi, Y., 1996. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. Journal of Drug Targeting 4, 1-8. 

  2. Auzenne, E., Ghosh, S., Khodadadian, M., Rivera, B., Farquhar, D., Price, R., Ravoori, M., Kundra, V., Freedman, R., Klostergaard, J., 2007. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44 (+) human ovarian carcinoma xenografts. Neoplasia (New York, NY) 9, 479. 

  3. Balazs, E., Denlinger, J., 1993. Viscosupplementation: a new concept in the treatment of osteoarthritis. Journal of rheumatology Supplement 20, 3-9. 

  4. Balazs, E., Leshchiner, A., 1987. Cross-linked gels of hyaluronic acid and products containing such gels. In: Google Patents. 

  5. Barbault-Foucher, S., Gref, R., Russo, P., Guechot, J., Bochot, A., 2002. Design of poly--caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. Journal of Controlled Release 83, 365-375. 

  6. Bernatchez, S.F., 1993. Ophthalmology. 

  7. Bothner, H., Wik, O., 1987. Rheology of hyaluronate. Acta Oto-Laryngologica 104, 25-30. 

  8. Bourguignon, L., Zhu, H., Shao, L., Chen, Y., 2000. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. Journal of Biological Chemistry 275, 1829. 

  9. Brown, M., Jones, S., 2005. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. Journal of the European Academy of Dermatology and Venereology 19, 308-318. 

  10. Bucolo, C., Mangiafico, P., 1999. Pharmacological profile of a new topical pilocarpine formulation. Journal of Ocular Pharmacology and Therapeutics 15, 567-573. 

  11. Camber, O., Edman, P., Gurny, R., 1987. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current eye research 6, 779-784. 

  12. Cascone, M., Sim, B., 1995. Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Biomaterials 16, 569-574. 

  13. Catterall, J., Jones, L., Turner, G., 1999. Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan. Clinical and Experimental Metastasis 17, 583-591. 

  14. Cho, K., Chung, T., Kim, B., Kim, M., Lee, J., Wee, W., Cho, C., 2003. Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro. International Journal of Pharmaceutics 260, 83-91. 

  15. Choi, K.Y., Chung, H., Min, K.H., Yoon, H.Y, Kim, K., Park, J.H., Kwon, I.C., Jeong, S.Y., 2010. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31, 106-114. 

  16. Chono, S., Li, S., Conwell, C., Huang, L., 2008. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. Journal of Controlled Release 131, 64-69. 

  17. Chun, K.W., Lee, J.B., Kim, S.H., Park, T.G., 2005. Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels. Biomaterials 26, 3319-3326. 

  18. Coradini, D., Pellizzaro, C., Miglierini, G., Daidone, M., Perbellini, A., 1999. Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. International Journal of Cancer 81, 411-416. 

  19. Culty, M., Shizari, M., Thompson, E., Underhill, C., 1994. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. Journal of cellular physiology 160, 275-286. 

  20. de la Fuente M., Seijo, B., Alonso, M., 2008a. Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules. Macromolecular bioscience 8, 441-450. 

  21. de la Fuente M., Seijo, B., Alonso, M.J., 2008b. Novel Hyaluronic Acid-Chitosan Nanoparticles for Ocular Gene Therapy. Investigative Ophthalmology & Visual Science 49, 2016-2024. 

  22. Dollo, G., Malinovsky, J., Peron, A., Chevanne, F., Pinaud, M., Verge, R., Corre, P., 2004. Prolongation of epidural bupivacaine effects with hyaluronic acid in rabbits. International Journal of Pharmaceutics 272, 109-119. 

  23. Edelstein, M., Abedi, M., Wixon, J., Edelstein, R., 2004. Gene therapy clinical trials worldwide 1989-2004-an overview. The journal of gene medicine 6, 597-602. 

  24. Elbert, D., Pratt, A., Lutolf, M., Halstenberg, S., Hubbell, J., 2001. Protein delivery from materials formed by self-selective conjugate addition reactions. Journal of Controlled Release 76, 11-25. 

  25. Eliaz, R., Szoka, Jr, F., 2001. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer research 61, 2592. 

  26. Esposito, E., Menegatti, E., Cortesi, R., 2005. Hyaluronan-based microspheres as tools for drug delivery: a comparative study. International Journal of Pharmaceutics 288, 35-49. 

  27. Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J., Kissel, T., 2003. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24, 1121-1131. 

  28. Goldman, C., Soroceanu, L., Smith, N., Gillespie, G., Shaw, W., Burgess, S., Bilbao, G., Curiel, D., 1997. In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nature biotechnology 15, 462-466. 

  29. Gurny, R., Ryser, J., Tabatabay, C., Martenet, M., Edman, P., Camber, O., 1990. Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy. Graefe's archive for clinical and experimental ophthalmology 228, 510-512. 

  30. Hahn, S., Jelacic, S., Maier, R., Stayton, P., Hoffman, A., 2004. Anti-inflammatory drug delivery from hyaluronic acid hydrogels. Journal of Biomaterials Science, Polymer Edition 15, 1111-1119. 

  31. Hahn, S., Oh, E., Miyamoto, H., Shimobouji, T., 2006. Sustained release formulation of erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition. International Journal of Pharmaceutics 322, 44-51. 

  32. Han, S.-E., Kang, H., Shim, G.Y., Kim S.J., Choi, H.-G., Kim, J., Hahn, S.K., Oh, Y.-K., 2009. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. Journal of Drug Targeting 17, 123-132. 

  33. Herbert, P., Murphy, K., Johnson, O., Dong, N., Jaworowicz, W., Tracy, M., Cleland, J., Putney, S., 1998. A large-scale process to produce microencapsulated proteins. Pharmaceutical research 15, 357-361. 

  34. Hirakura, T., Yasugi, K., Nemoto, T., Sato, M., Shimoboji, T., Aso, Y., Morimoto, N., Akiyoshi, K., 2009. Hybrid hyaluronan hydrogel encapsulating nanogel as a protein nanocarrier: New system for sustained delivery of protein with a chaperone-like function. Journal of Controlled Release. 

  35. Hornof, M., de la Fuente, M., Hallikainen, M., Tammi, R.H., Urtti, A., 2008. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. The journal of gene medicine 10, 70-80. 

  36. Horvat, S., Feher, A., Wolburg, H., Sipos, P., Veszelka, S., Toth, A., Kis, L., Kurunczi, A., Balogh, G., Kurti, L., 2009. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. European journal of pharmaceutics and biopharmaceutics 72, 252-259. 

  37. Huh, Y., Cho, H., Yoon, I., Choi, M., Kim, J., Oh, E., Chung, S., Shim, C., Kim, D., 2010. Preparation and evaluation of spraydried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride. European Journal of Pharmaceutical Sciences. 

  38. Hume, L., Lee, H., Benedetti, L., Sanzgiri, Y., Topp, E., Stella, V., 1994. Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films. International Journal of Pharmaceutics 111, 295-298. 

  39. Illum, L., Farraj, N., Fisher, A., Gill, I., Miglietta, M., Benedetti, L., 1994. Hyaluronic acid ester microspheres as a nasal delivery system for insulin. Journal of Controlled Release 29, 133-141. 

  40. Ito, T., Iidatanaka, N., Niidome, T., Kawano, T., Kubo, K., Yoshikawa, K., Sato, T., Yang, Z., Koyama, Y., 2006. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: Protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. Journal of Controlled Release 112, 382-388. 

  41. Ito, T., Yoshihara, C., Hamada, K., Koyama, Y., 2010. DNA/polyethyleneimine/ 

  42. Jeong, B., Bae, Y., Kim, S., 2000. Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. Journal of Controlled Release 63, 155-163. 

  43. Jeong, B., Lee, K., Gutowska, A., An, Y., 2002. % Thermogelling Biodegradable Copolymer Aqueous Solutions for Injectable Protein Delivery and Tissue Engineering. Biomacromolecules 3, 865-868. 

  44. Jiang, G., Park, K., Kim, J., Kim, K., Hahn, S., 2009. Target Specific Intracellular Delivery of siRNA/PEI- HA Complex by Receptor Mediated Endocytosis. Molecular Pharmaceutics 6, 727-737. 

  45. Jiang, H., Wang, Y., Huang, Q., Li, Y., Xu, C., Zhu, K., Chen, W., 2005. Biodegradable hyaluronic acid/N-carboxyethyl chitosan/protein ternary complexes as implantable carriers for controlled protein release. Macromolecular bioscience 5, 1226-1233. 

  46. Johnson, O., Cleland, J., Lee, H., Charnis, M., Duenas, E., Jaworowicz, W., Shepard, D., Shahzamani, A., Jones, A., Putney, S., 1996. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Medicine 2, 795-799. 

  47. Kim, A., 2005. Delivery of a vector encoding mouse hyaluronan synthase 2 via a crosslinked hyaluronan film. Biomaterials 26, 1585-1593. 

  48. Kim, A., Checkla, D., Dehazya, P., Chen, W., 2003. Characterization of DNA-hyaluronan matrix for sustained gene transfer. Journal of Controlled Release 90, 81-95. 

  49. Kim, E.-J., Shim, G., Kim, K., Kwon, I.C., Oh, Y.-K., Shim, C.-K., 2009. Hyaluronic acid complexed to biodegradable poly Larginine for targeted delivery of siRNAs. The journal of gene medicine 11, 791-803. 

  50. Kim, M., Park, T., 2002. Temperature-responsive and degradable hyaluronic acid/Pluronic composite hydrogels for controlled release of human growth hormone. Journal of Controlled Release 80, 69-77. 

  51. Kim, S., Hahn, S., Kim, M., Kim, D., Lee, Y., 2005. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. Journal of Controlled Release 104, 323-335. 

  52. Kobayashi, Y., Okamoto, A., Nishinari, K., 1994. Viscoelasticity of hyaluronic acid with different molecular weights. Biorheology 31, 235-244. 

  53. Kumar, A., Sahoo, B., Montpetit, A., Behera, S., Lockey, R., Mohapatra, S., 2007. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine: Nanotechnology, Biology and Medicine 3, 132-137. 

  54. Kuo, J., Swann, D., Prestwich, G., 1991. Chemical modification of hyaluronic acid by carbodiimides. Bioconjugate Chemistry 2, 232-241. 

  55. Kyyronen, K., Hume, L., Benedetti, L., Urtti, A., Topp, E., Stella., V., 1992. Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release studies. International Journal of Pharmaceutics 80, 161-169. 

  56. Laurent, T., 1998. The chemistry, biology and medical applications of hyaluronan and its derivatives: Portland Pr. 

  57. Le Bourlais, C., Acar, L., Zia, H., Sado, P., Needham, T., Leverge, R., 1998. Ophthalmic drug delivery systems--recent advances. Progress in retinal and eye research 17, 33-58. 

  58. Lee, B., West, B., McLemore, R., Pauken, C., Vernon, B., 2006. Insitu injectable physically and chemically gelling NIPAAmbased copolymer system for embolization. Biomacromolecules 7, 2059-2064. 

  59. Lee, E., Kwon, M., Na, K., Bae, J., 2007a. Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex. Colloids and Surfaces B: Biointerfaces 55, 125-130. 

  60. Lee, F., Chung, J., Kurisawa, M., 2009. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. Journal of Controlled Release 134, 186-193. 

  61. Lee, H., Mok, H., Lee, S., Oh, Y., Park, T., 2007b. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. Journal of Controlled Release 119, 245-252. 

  62. Lim, S., Martin, G., Berry, D., Brown, M., 2000. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. Journal of Controlled Release 66, 281-292. 

  63. Lin, Q.-K., Ren, K.-F., Ji, J., 2009. Hyaluronic acid and chitosan-DNA complex multilayered thin film as surface-mediated nonviral gene delivery system. Colloids and Surfaces B: Biointerfaces 74, 298-303. 

  64. Ludwig, A., 2005. The use of mucoadhesive polymers in ocular drug delivery. Advanced drug delivery reviews 57, 1595-1639. 

  65. Luo, Y., Bernshaw, N., Lu, Z., Kopecek, J., Prestwich, G., 2002. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharmaceutical research 19, 396-402. 

  66. Luo, Y., Kirker, K., Prestwich, G., 2000. Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery. Journal of Controlled Release 69, 169-184. 

  67. Lutolf, M., Lauer-Fields, J., Schmoekel, H., Metters, A., Weber, F., Fields, G., Hubbell, J., 2003. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proceedings of the National Academy of Sciences of the United States of America 100, 5413. 

  68. Maeda, H., Seymour, L., Miyamoto, Y., 1992. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate chemistry 3, 351-362. 

  69. Marshall, K., 2000. Intra-articular hyaluronan therapy. Current opinion in rheumatology 12, 468. 

  70. Matsubara, Y., Katoh, S., Taniguchi, H., Oka, M., Kadota, J., Kohno, S., 2000. Expression of CD44 Variants in Lung Cancer and Its Relationship to Hyaluronan Binding. The Journal of International Medical Research 28, 78-90. 

  71. Mok, H., Park, J., Park, T., 2007. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. Bioconjugate Chem 18, 1483-1489. 

  72. Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi Y., Nakai, Y., 1991. Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analogue. Pharmaceutical research 8, 471-474. 

  73. Moriyama, K., Ooya, T., Yui, N., 1999. Hyaluronic acid grafted with poly (ethylene glycol) as a novel peptide formulation. Journal of Controlled Release 59, 77-86. 

  74. Necas, J., Bartosikova, L., Brauner, P., Kolar, J., 2008. Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina 53, 397-411. 

  75. Oh, E., Park, K., Kim, K., Kim, J., Yang, J., Kong, J., Lee, M., Hoffman, A., Hahn, S., 2010. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. Journal of Controlled Release 141, 2-12. 

  76. Ohri, R., Hahn, S., Hoffman, A., Stayton, P., Giachelli, C., 2004. Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium. Journal of Biomedical Materials Research Part A 70, 328-334. 

  77. Park, J., Chakrabarti, B., 1978. Conformational transition of hyaluronic acid carboxylic group participation and thermal effect. Biochimica et Biophysica Acta (BBA)-General Subjects 541, 263-269. 

  78. Peer, D., Margalit, R., 2004. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. International Journal of Cancer 108, 780-789. 

  79. Prestwich, G., Marecak, D., Marecek, J., Vercruysse, K., Ziebell, M., 1998. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. Journal of Controlled Release 53, 93-103. 

  80. Price, R., Berry, M., Navsaria, H., 2007. Hyaluronic acid: the scientific and clinical evidence. Journal of Plastic, Reconstructive & Aesthetic Surgery 60, 1110-1119. 

  81. Prisell, P., Camber, O., Hiselius, J., Norstedt, G., 1992. Evaluation of hyaluronan as a vehicle for peptide growth factors. International Journal of Pharmaceutics 85, 51-56. 

  82. Rydell, N., Balazs, E., 1971. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 80, 25. 

  83. Saraf, A., Hacker, M., Sitharaman, B., Grande-Allen, K., Barry, M., Mikos, A., 2008. Synthesis and conformational evaluation of a novel gene delivery vector for human mesenchymal stem cells. Biomacromolecules 9, 818-827. 

  84. Schiffelers, R., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P., Scaria, P., Woodle, M., 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic acids research 32, e149. 

  85. Segura, T., 2005. DNA delivery from hyaluronic acid-collagen hydrogels via a substrate-mediated approach. Biomaterials 26, 1575-1584. 

  86. Shim, W., Yoo, J., Bae, Y., Lee, D., 2005. Novel injectable pH and temperature sensitive block copolymer hydrogel. Biomacromolecules 6, 2930-2934. 

  87. Shu, X., Liu, Y., Luo, Y., Roberts, M., Prestwich, G., 2002. Disulfide cross-linked hyaluronan hydrogels. Biomacromolecules 3, 1304-1311. 

  88. Singh, M., Briones, M., O'Hagan, D., 2001. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. Journal of Controlled Release 70, 267-276. 

  89. Sintzel, M., Bernatchez, S., Tabatabay, C., Gurny, R., 1996. Biomaterials in ophthalmic drug delivery. European journal of pharmaceutics and biopharmaceutics 42, 358-374. 

  90. Sun, X., Ma, P., Cao, X., Ning, L., Tian, Y., Ren, C., 2009. Positive hyaluronan/PEI/DNA complexes as a target-specific intracellular delivery to malignant breast cancer. Drug Delivery 16, 357-362. 

  91. Surace, C., Arpicco, S., Dufay -Wojcicki, A., Marsaud, V., Bouclier, C., Clay, D., Cattel, L., Renoir, J., Fattal, E., 2009. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Molecular Pharmaceutics 6, 1062-1073. 

  92. Surendrakumar, K., Martyn, G., Hodgers, E., Jansen, M., Blair, J., 2003. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. Journal of Controlled Release 91, 385-394. 

  93. Takei, Y., Maruyama, A., Ferdous, A., Nishimura, Y., Kawano, S., Ikejima, K., Okumura, S., Asayama, S., Nogawa, M., Hashimoto, M., 2004. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronanglycocalyx. The FASAB Journal 18: 699-701. 

  94. Tammi, R., Ripellino, J., Margolis, R., Tammi, M., 1988. Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe. Journal of Investigative Dermatology 90, 412-414. 

  95. Tracy, M., 1998. Development and scale-up of a microsphere protein delivery system. Biotechnology progress 14, 108-115. 

  96. Turker, S., Onur, E., Ozer, Y., 2004. Nasal route and drug delivery systems. Pharmacy World & Science 26, 137-142. 

  97. Ugwoke, M., Agu, R., Verbeke, N., Kinget, R., 2005. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Advanced drug delivery reviews 57, 1640-1665. 

  98. Upadhyay, K.K., Bhatt, A.N, Mishra, A.K., Dwarakanath, B.S., Jain, S., Schatz, C., Le Meins, J.-F., Farooque, A., Chandraiah, G., Jain, A.K., 2010. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly( ${\gamma}$ -benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials 31, 2882-2892. 

  99. Varma, R., Varma, R., Allen, W., Wardi, A., 1975. Human umbilical cord hyaluronate neutral sugar content and carbohydrateprotein linkage studies. Biochimica et Biophysica Acta (BBA)-General Subjects 399, 139-144. 

  100. West, D., Hampson, I., Arnold, F., Kumar, S., 1985. Angiogenesis induced by degradation products of hyaluronic acid. Science 228, 1324-1326. 

  101. Wieland, J., Houchinray, T., Shea, L., 2007. Non-viral vector delivery from PEG-hyaluronic acid hydrogels. Journal of Controlled Release 120, 233-241. 

  102. Wilson, A., Zhou, W., Champion, H., Alber, S., Tang, Z., Kennel, S., Watkins, S., Huang, L., Pitt, B., Li, S., 2005. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Molecular Therapy 12, 510-518. 

  103. Xie, Y., Aillon, K.L., Cai, S., Christian, J.M, Davies NM, Berkland CJ, Forrest ML. 2010. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. International Journal of Pharmaceutics 392, 156-163. 

  104. Xu, P., Quick, G.K., Yeo, Y., 2009. Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials 30, 5834-5843. 

  105. Yenice, I., Mocan, M., Palaska, E., Bochot, A., Bilensoy, E., Vural, I., Irkec, M., Atillahincal, A., 2008. Hyaluronic acid coated poly--caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Experimental Eye Research 87, 162-167. 

  106. Yokota, A., Ishii, G., Sugaya, Y., Nishimura, M., Saito, Y., Harigaya, K., 1999. Potential use of serum CD44 as an indicator of tumour progression in acute leukemia. Hematological Oncology 17, 161-168. 

  107. Yun, Y., 2004. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials 25, 147-157. 

저자의 다른 논문 :

관련 콘텐츠

오픈액세스(OA) 유형

GOLD(Hybrid)

저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로